[A presumed transient hemolytic reaction following vinca alkaloids administration in patients with hematological malignancies].
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced*; D007945:Leukemia, Lymphoid / Q000097:blood / Q000188:drug therapy*; D008223:Lymphoma / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives*; D014750:Vincristine / Q000009:adverse effects*; D014751:Vindesine
D014750:Vincristine; D014747:Vinblastine; D014751:Vindesine